Remove 2025 Remove Drug Development Remove Interoperability
article thumbnail

Future HealthTech Valuations in 2025: A Dynamic Landscape

Lloyd Price

In 2025, HealthTech valuations are expected to continue their upward trajectory, driven by several key factors: 1. Technological Advancements: AI and Machine Learning: AI-powered diagnostics, drug discovery, and personalised medicine are revolutionising healthcare.

article thumbnail

HealthTech M&A 2025 Predictions: Europe and USA

Lloyd Price

Exec Summary: The HealthTech sector is poised for significant M&A activity in 2025, driven by several key trends: Digital Health Solutions: The increasing demand for digital health solutions to improve healthcare accessibility and efficiency will drive acquisitions of innovative startups and established players in this space.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The 4 Big Gaps in HealthTech: Funding, Trust, Evidence, Valuation

Lloyd Price

Regulatory Hurdles: The stringent regulatory environment in healthcare can increase development costs and delay time to market, making it less attractive to investors. Interoperability Standards: Support the adoption of standardized data formats and interoperability standards. Regularly assess and update security protocols.

article thumbnail

House Task Force AI Policy Recommendations

Digital Health Wire

The task force started by highlighting AIs potential across a long list of use cases, which could have been the tracklist for healthcares greatest hits of 2024: Drug Development – 300+ drug applications contained AI components this year. Ambient AI – Burnout is bad. Patient time is good.